株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

高成長の診断検査市場

High-Growth Diagnostic Testing Markets

発行 TriMark Publications 商品コード 243428
出版日 ページ情報 英文 355 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: TriMark Publications社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
高成長の診断検査市場 High-Growth Diagnostic Testing Markets
出版日: 2016年01月01日 ページ情報: 英文 355 Pages
担当者のコメント
米国ニューヨークに本社を置くTriMark Publicationsは、IVDやPOC等の診断検査分野のリサーチに定評のある市場調査会社です。独自のデータベースを有し、情報のアップデートにともない更新版が発行されることから、継続的に購入されるお客様の多い人気のレポートです。
概要

医療の質向上とコスト削減が求められる中、今後5年間で、新たな診断検査サービスの需要が着実に増加するものとみられています。

当レポートでは、米国をはじめ世界の高成長の診断検査市場について検証し、市場の規模と成長牽引因子、新製品や業界動向、今後の市場予測などをまとめております。

第1章 概要

第2章 高成長の検査市場のイントロダクション

  • 世界の診断市場のイントロダクション
  • 高成長検査の潜在能力をもつ領域
  • 高成長の診断検査部門における市場促進因子
  • 高成長検査の市場セグメント
  • 高成長の診断検査セグメントにおける主要企業
  • 高成長検査部門分析

第3章 肝炎血清市場と核酸検査

  • B型肝炎ウイルス (HBV)
  • B型肝炎ウイルス検査製品の主なサプライヤー
  • 市場収益分析
  • C型肝炎ウイルス検査 (HCV)
  • 市場収益分析

第4章 ヒトパピローマウイルス (HPV) 検査

  • 概要
  • HPVと子宮頸がんの関係
  • PAP検査
  • 現在の試験所におけるHPV検出方法
    • 直接プローブ法
    • 信号増幅
    • 標的増幅
  • HPVのアッセイ
  • 市場収益分析
    • 北米市場
    • 欧州市場
  • 市場・技術動向
    • 市場動向
    • 技術動向

第5章 HIV

  • HIV/AIDSのイントロダクション
  • 市場ダイナミクス
    • 促進因子
    • 抑制因子
    • 市場動向
    • 技術動向
  • HIV検査デバイスのレビュー
    • 装置およびMDx試薬
  • 市場分析
  • 競合企業の活動
  • HIV市場の課題と戦略的提言
  • 保険適用と償還

第6章 感染病検査

  • 感染病検査のイントロダクション
  • 感染病の診断の種類
    • 微生物培養
    • 顕微鏡
    • 生化学的検査
    • 分子診断
  • 感染症診断プラットフォーム
    • 感染症の中央検査室
    • 感染症のPOC
  • 新興技術
  • 定性分析
    • 促進因子
    • 抑制因子
  • 連鎖球菌検査
  • クラミジア検査
  • 単核球
  • 淋病
  • インフルエンザ
  • マラリア
  • 結核
  • メチシリン耐性黄色ブドウ球菌 (MRSA)
  • 市場収益予測

第7章 心臓マーカー

  • 市場概要
  • 心臓マーカー検査
    • クレアチンキナーゼ (CK)
    • ミオグロビン
    • 心臓トロポニン T (TnT) 、 I (TnI) およびC (TnC)
    • C反応性タンパク質 (CRP)
    • ホモシステイン
  • 新興マーカー
    • B型ナトリウム利尿ペプチド (BNP)
    • ミエロペルオキシダーゼ (MPO)
    • 虚血変性アルブミン (IMA)
    • グリコーゲンホスホリラーゼアイソザイムBB (GPBB)
    • 脂肪酸結合タンパク質 (FABP)
  • 特殊心臓疾患
    • 急性心筋梗塞
    • 心不全 (BNP)
    • CRP
  • 肺塞栓症 (Dダイマー検査)
  • 主要企業
  • 市場収益分析

第8章 細胞遺伝学検査

  • 癌検査
  • 出生前検査と細胞遺伝学
    • 嚢胞性線維症検査

第9章 癌バイオマーカー検査

  • セグメント概要
  • 癌検査市場
  • 競争
  • 個別市場
    • 悪性腫瘍病理学:検査
    • 乳がん
    • 卵巣がん
    • 子宮頸がん
    • 結腸がんDNA検査
  • 薬理ゲノム癌検査
  • 市場収益分析

第10章 薬物乱用検査

  • POC薬物乱用検査の背景
  • 薬物乱用検査の種類
  • アルコール依存症・スクリーニング
  • 唾液検査
  • 定性分析
  • 主なPOC薬物乱用アナライザーのレビュー
  • 製品レビュー

第11章 ビタミンD診断検査

  • 市場収益分析

第12章 コンパニオン診断

  • 市場収益分析

第13章 世界のIVD高成長市場のサマリー分析:地域別

第14章 臨床試験所のゲノミクス

第15章 細胞画像細胞病理学と組織病理学

第16章 高成長の検査診断動向

第17章 重要な技術動向

第18章 分子診断:主な診断技術の進歩

第19章 POCTにおける技術プラットフォームの技術革新

第20章 データマネジメントと接続性

第21章 臨床のためのバイオチップ

第22章 企業プロファイル

  • Abbott Laboratories
  • Alere, Inc.
  • Beckman Coulter (now part of Danaher)
  • Becton, Dickinson and Company
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Chembio Diagnostics, Inc.
  • Hologic Gen Probe
  • Johnson & Johnson
  • OraSure
  • QIAGEN N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TMRHGD16-0101

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.

Table of Contents

1. Overview

  • 1.1 Statement of Report
  • 1.2 Scope of This Report
  • 1.3 Methodology
  • 1.4 Executive Summary

2. Introduction to the High-Growth Testing Market

  • 2.1 Introduction to the Global Diagnostic Market
  • 2.2 General Areas with Potential for High-Growth Testing
  • 2.3 Market Drivers in the High-Growth Diagnostics Testing Sector
  • 2.4 Market Segments for High-Growth Testing
  • 2.5 Key Players in the High-Growth Diagnostics Testing Segment
  • 2.6 High-Growth Testing Sector Analysis

3. Hepatitis Serologic Markers and Nucleic Acid Testing

  • 3.1 Hepatitis B Virus (HBV)
  • 3.2 Major Suppliers of Hepatitis B Virus (HBV) Testing Products
  • 3.3 Market Revenue Analysis
  • 3.4 Hepatitis C Virus (HCV) Testing
  • 3.5 Market Analysis
    • 3.5.1 HCV Market Share

4. Human Papillomavirus (HPV) Testing

  • 4.1 Overview
  • 4.2 The Association of HPV and Cervical Cancer
  • 4.3 The PAP Test
  • 4.4 Current Laboratory Methods for HPV Detection
    • 4.4.1 Direct-Probe Methods
    • 4.4.2 Signal Amplification
    • 4.4.3 Target Amplification
  • 4.5 Assays for HPV
  • 4.6 Market Revenue Analysis
    • 4.6.1 North American Market
    • 4.6.2 European Market
  • 4.7 Market and Technology Trends
    • 4.7.1 Market Trends
    • 4.7.2 Technology Trends

5. HIV

  • 5.1 Introduction to HIV/AIDS
  • 5.2 Market Dynamics
    • 5.2.1 Market Drivers
    • 5.2.2 Market Restraints
    • 5.2.3 Market Trends
    • 5.2.4 Technology Trends
  • 5.3 Review of Selected HIV Testing Devices
    • 5.3.1 Instruments and MDx Reagents
  • 5.4 Market Analysis
  • 5.5 Competitor Activity
  • 5.6 HIV Market Challenges and Strategic Recommendations
  • 5.7 Insurance Coverage and Reimbursement

6. Infectious Disease Testing

  • 6.1 Introduction to Infectious Disease Testing
  • 6.2 Types of Diagnosis for Infectious Diseases
    • 6.2.1 Microbial Culture
    • 6.2.2 Microscopy
    • 6.2.3 Biochemical Tests
    • 6.2.4 Molecular Diagnostics
  • 6.3 Diagnostic Platforms for Infectious Diseases
    • 6.3.1 Centralized Laboratory Testing for Infectious Diseases
    • 6.3.2 POC Testing for Infectious Diseases
  • 6.4 Emerging Technologies
  • 6.5 Qualitative Analysis
    • 6.5.1 Market Drivers
    • 6.5.2 Market Restraints
  • 6.6 Streptococcus Testing
  • 6.7 Chlamydia Testing
  • 6.8 Mononucleosis
  • 6.9 Gonorrhea
  • 6.10 Influenza
  • 6.11 Malaria
  • 6.12 Tuberculosis
  • 6.13 Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 6.14 Market Revenue Analysis

7. Cardiac Markers

  • 7.1 Market Overview
  • 7.2 Cardiac Marker Tests
    • 7.2.1 Creatine Kinase (CK)
    • 7.2.2 Myoglobin
    • 7.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC)
    • 7.2.4 C-Reactive Protein (CRP)
    • 7.2.5 Homocysteine
  • 7.3 Emerging Markers
    • 7.3.1 B-type Natriuretic Peptide (BNP)
    • 7.3.2 Myeloperoxidase (MPO)
    • 7.3.3 Ischemia Modified Albumin (IMA)
    • 7.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB)
    • 7.3.5 Fatty Acid-Binding Proteins (FABPs)
  • 7.4 Qualitative Analysis
    • 7.4.1 Market Drivers
    • 7.4.2 Market Restraints
  • 7.5 Specific Cardiac Conditions
    • 7.5.1 Acute Myocardial Infarction
    • 7.5.2 Heart Failure (BNP)
      • 7.5.2.1 Market Overview
      • 7.5.2.2 Commercial Assays for BNP and NT-proBNP
      • 7.5.2.3 Clinical Applications of BNP
    • 7.5.3 CRP
  • 7.6 Pulmonary Embolism (D-dimer Test)
  • 7.7 Key Players
  • 7.8 Market Revenue Analysis

8. Cytogenetic Testing

  • 8.1 Cancer Testing
  • 8.2 Prenatal Testing and Cytogenetics
    • 8.2.1 Cystic Fibrosis Testing
      • 8.2.1.1 CF Testing Methodology
      • 8.2.1.2 CF Screening Technology Summary

9. Cancer Biomarker Testing

  • 9.1 Segment Overview
  • 9.2 The Cancer Testing Market
  • 9.3 Competition
  • 9.4 Individual Markets
    • 9.4.1 Cancer Pathology: Testing
      • 9.4.1.1 Rare Cell/Micro Metastasis Detection
      • 9.4.1.2 Cancer Pathology: High-Throughput Screening
      • 9.4.1.3 Competition
      • 9.4.1.4 Drivers
    • 9.4.2 Breast Cancer
      • 9.4.2.1 CA 15-3
      • 9.4.2.2 CA 27-29
      • 9.4.2.3 BRCA1 and BRCA2 Breast and Ovarian Cancer Genes 174
      • 9.4.2.4 Estrogen and Progesterone Receptor (ER and PR) 176
      • 9.4.2.5 Human Epidermal Growth Factor Receptor 2 (HER-2)
      • 9.4.2.6 Herceptin
      • 9.4.2.7 p53
      • 9.4.2.8 MammaPrint
      • 9.4.2.9 Drivers for Breast Cancer Test Development
      • 9.4.2.9.1 Breast Cancer Molecular Diagnostic Testing Assay Market Trends
      • 9.4.2.9.2 Breast Cancer Molecular Diagnostic Testing Assay Technology Trends
      • 9.4.2.9.3 Breast Cancer Testing Assay Strategic Recommendations
    • 9.4.3 Ovarian Cancer
      • 9.4.3.1 Cancer Antigen 125 (CA
      • 9.4.3.2 BRCA1 and BRCA2
      • 9.4.3.3 Epidermal Growth Factor Receptor (EGFR)
    • 9.4.4 Cervical Cancer
      • 9.4.4.1 Cervical Cancer Screening Tests
    • 9.4.5 Colon Cancer DNA Testing
  • 9.5 Pharmacogenomic Cancer Testing
  • 9.6 Market Revenue Analysis

10. Substance Abuse Testing

  • 10.1 Background to POC Substance Abuse Testing
  • 10.2 Substance Abuse Test Types
    • 10.2.1 Urine Substance/Drug Screening
    • 10.2.2 Hair Tests for Substance Abuse and Screening
    • 10.2.3 Blood Tests for Substance Abuse and Screening
    • 10.2.4 Saliva Tests for Substance Abuse and Screening
    • 10.2.5 Sweat Tests for Substance Abuse and Screening
  • 10.3 Alcohol Abuse and Screening
  • 10.4 Saliva Testing
  • 10.5 Qualitative Analysis
    • 10.5.1 Market Drivers
    • 10.5.2 Market Restraints
  • 10.6 Review of Selected POC Substance Abuse Analyzers
  • 10.7 Review of Company Products
    • 10.7.1 Alere
    • 10.7.2 Abbott Diagnostics
    • 10.7.3 BioScan Screening Systems, Inc.
    • 10.7.4 American Bio Medica Corporation
    • 10.7.5 Phamatech, Inc.
    • 10.7.6 OraSure Technologies, Inc.
    • 10.7.7 Alfa Scientific Designs, Inc.
    • 10.7.8 Branan Medical

11. Vitamin D Diagnostic Testing

  • 11.1 Market Revenue Analysis

12. Companion Diagnostics

  • 12.1 Market Revenue Analysis

13. Summary Analysis of the Global IVD High-Growth Market by Geographic Region

  • 13.1 Summary Analysis of the Global IVD Market
  • 13.2 Summary Analysis of the Global IVD High-Growth Market by Geographic Region
  • 13.3 U.S.: Summary Analysis of the IVD High-Growth Market
    • 13.3.1 Cardiac Markers
  • 13.4 Europe: Summary Analysis of the IVD High-Growth Market
    • 13.4.1 Summary of IVD High-Growth Market Europe
  • 13.5 Brazil: Summary Analysis of the IVD High-Growth Market
    • 13.5.1 Summary of IVD High-Growth Market Brazil
  • 13.6 Russia: Summary Analysis of the IVD High-Growth Market
    • 13.6.1 Summary of IVD High-Growth Market Russia
  • 13.7 India: Summary Analysis of the IVD High-Growth Market
    • 13.7.1 Summary of IVD High-Growth Market India
  • 13.8 China: Summary Analysis of the IVD High-Growth Market
    • 13.8.1 Summary of IVD High-Growth Market China
  • 13.9 South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market
    • 13.9.1 Japan
    • 13.9.2 South Korea
    • 13.9.3 Rapid Growth Market of IVD HIV/AIDS Testing in Other Asia
    • 13.9.4 Summary of IVD High-Growth Market Other Asia

14. Clinical Laboratory Genomics

  • 14.1 Introduction
  • 14.2 Clinical Laboratory Genomics Testing
  • 14.3 Developments in Clinical Laboratory Genomics
    • 14.3.1 Nucleic Acid Amplification Techniques
    • 14.3.2 Chromosome Imaging
    • 14.3.3 Genomics Technologies
    • 14.3.4 Proteomics Technology
    • 14.3.5 Current Pharmacogenomic Tests
    • 14.3.6 Future Pharmacogenomic Testing

15. Cellular Imaging Cytopathology and Histopathology

  • 15.1 Segment Overview
  • 15.2 The Market
  • 15.3 Market Drivers
  • 15.4 Market Restraints
  • 15.5 Cytology and Histology Technology Platforms
    • 15.5.1 Cytology Screening Procedures and Pap Smear Technology
    • 15.5.2 Histology
    • 15.5.3 Market Drivers
    • 15.5.4 ISH Staining
    • 15.5.5 Special-Stains Staining
  • 15.6 Third-Party Reimbursement

16. High-Growth Testing Diagnostic Trends

  • 16.1 Genetic Testing
  • 16.2 Quality Measures
  • 16.3 Moderators of Growth
    • 16.3.1 Diagnostics and the Aging Population
    • 16.3.2 Individualized Medicine
    • 16.3.3 Genetic Testing
  • 16.4 Workforce Issues
  • 16.5 Reimbursement
    • 16.5.1 Cardiovascular
    • 16.5.2 Screening for Diabetes
    • 16.5.3 CPT Test Codes and Payment Amounts
  • 16.6 Rapid Near-Patient Testing in Hospitals
  • 16.7 Satellite Facilities
  • 16.8 Regionalization of Laboratory Care
  • 16.9 Requirements for High-Growth Testing
  • 16.10 Clinical Laboratory Improvement Act (CLIA)

17. Important Technology Trends

18. Molecular Diagnostics a Major Diagnostic Technological Advance

  • 18.1 Polymerase Chain Reaction (PCR)-Based Molecular Diagnostics
  • 18.2 Micrarray Technologies and Molecular Diagnostics
  • 18.3 Isothermal Amplification Technologies and Molecular Diagnostics
  • 18.4 Miniaturization Technologies and Molecular Diagnostics (Biochips and Lab on a Chip)

19. Technology Platform Innovations in POCT

  • 19.1 The Biggest New Opportunities in POCT
  • 19.2 Latest POCT Technological Platforms
    • 19.2.1 Device Miniaturization and Microfluidic Technologies
    • 19.2.2 Minimally-Invasive and Non-Invasive POCT Technologies
    • 19.2.3 Advances in Wireless Technologies
    • 19.2.4 Automation of POCT
    • 19.2.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies)
    • 19.2.6 Advances in Informatics Technologies
    • 19.2.7 Pharmacogenetic Testing
    • 19.2.8 Multi Assay Technologies in POCT
  • 19.3 Developments in Key Technologies
    • 19.3.1 Medical and Biological Sensors and Sensor Systems
    • 19.3.2 Recent Biosensor Product Introductions and Latest Innovative Developments
      • 19.3.2.1 Nanoscale Sensors for the Detection of Cancer Biomarkers
      • 19.3.2.2 ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments
  • 19.4 Sensor Systems for Diagnostic Applications
  • 19.5 Nanogen (The ELITech Group) Third Generation Point of Care Analyzer
  • 19.6 Philips Development of Magnotech Technology
  • 19.7 Quidel Corporation MChip, AVR Chip and F Chip
  • 19.8 Sanofi-Aventis

20. Data Management and Connectivity

  • 20.1 Wireless LANs
  • 20.2 Connectivity Platforms
    • 20.2.1 DataLink Data Management System
    • 20.2.2 International Technidyne Corporation HEMOCHRON Signature Elite
    • 20.2.3 Siemens Diagnostics RAPIDPoint 500
    • 20.2.4 Alere Connect Products
    • 20.2.5 Medical Implant Communications Service (MICS)
    • 20.2.6 Conworx Technology
    • 20.2.7 Alere Informatics
    • 20.2.8 Medasys
    • 20.2.9 NoemaLife
  • 20.3 Advantages of Connectivity
    • 20.3.1 Cost Benefit of POCT and IT Connectivity
    • 20.3.2 Hospital Network Issues
  • 20.4 Analyzer Connectivity Software Solutions

21. Biochips for Clinical Applications

  • 21.1 Breast Cancer DNA Chips

22. Company Profiles

  • 22.1 Abbott Laboratories
  • 22.2 Alere, Inc.
  • 22.3 Beckman Coulter (now part of Danaher)
  • 22.4 Becton, Dickinson and Company
  • 22.5 Biomerica, Inc.
  • 22.6 Bio-Rad Laboratories, Inc.
  • 22.7 Chembio Diagnostics, Inc.
  • 22.8 Hologic Gen Probe
  • 22.9 Johnson & Johnson
  • 22.10 OraSure
  • 22.11 QIAGEN N.V.
  • 22.12 Quidel Corporation
  • 22.13 Roche Diagnostics
  • 22.14 Siemens Healthcare Diagnostics

INDEX OF FIGURES

  • Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market,
  • Figure 1.2: Worldwide Geographic Distribution of Total IVD Testing Markets by Country,
  • Figure 1.3: Company Market Share for IVD Testing Markets,
  • Figure 3.1: Geographic Distribution of Chronic HBV Infection
  • Figure 3.2: Evolution of HBV Markers in Acute and Chronic Infection
  • Figure 3.3: U.S. Market Share of HCV Molecular Diagnostic Market,
  • Figure 3.4: Global Market Share (Excluding U.S.) of HCV Molecular Diagnostic Market,
  • Figure 4.1: Hybrid Capture
  • Figure 4.2: Basic Steps in Hybrid Capture
  • Figure 4.3: U.S. Market Share of HPV Molecular Diagnostic Market,
  • Figure 4.4: Global Market Share (Excluding U.S.) of HPV Molecular Diagnostic Market,
  • Figure 4.5: Market Share Estimates for Molecular Diagnostic HPV Testing,
  • Figure 5.1: Ten Best Selling AIDS Drugs in the U.S.,
  • Figure 5.2: U.S. Rates for New HIV Cases,
  • Figure 5.3: U.S. Rates for New HIV Cases in Men,
  • Figure 5.4: U.S. Rates for New HIV Cases in Women,
  • Figure 5.5: Estimated Market for Global HIV Molecular Diagnostic Testing,
  • Figure 5.6: Estimated Market for U.S. HIV Molecular Diagnostic Testing,
  • Figure 5.7: Market Share Viral Load HIV Molecular Diagnostic Testing
  • Figure 6.1: U.S. and Outlying Areas Gonorrhea Infection Rates,
  • Figure 6.2: Mode of Action of Common Malaria RDT Format
  • Figure 6.3: Rate of Tuberculosis Cases by State/Area in the U.S.,
  • Figure 6.4: U.S.-Born Tuberculosis Cases by Ethnicity,
  • Figure 6.5: FIND Pipeline for TB Diagnostics
  • Figure 13.1: Worldwide Geographic Distribution of Total IVD Testing Market,
  • Figure 13.2: Worldwide Geographic Distribution of Total IVD Testing Markets by Country,
  • Figure 13.3: Company Market Share for IVD Testing Markets,
  • Figure 13.4: U.S. Cardiac Marker Diagnostic Testing Market Segments,
  • Figure 13.5: Cardiac Marker Market for Diagnostic Testing in Europe,
  • Figure 13.6: Indian Diagnostics Market Segments,
  • Figure 13.7: The Chinese Healthcare System
  • Figure 20.1: The RALS Data Management System Connects to Most of the Major Instruments Used in Point of Care
  • Figure 20.2: RALS-Freedom Point of Care and Critical Care Connectivity and Information Management System

INDEX OF TABLES

  • Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments
  • Table 1.2: Market Trends in the High-Growth Diagnostics Space
  • Table 1.3: Global Distribution of IVD Testing by Key Geographic Regions,
  • Table 1.4: Top
  • Table 1.5: Company Market Share for IVD Testing Markets,
  • Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing,
  • Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment,
  • Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region,
  • Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections
  • Table 3.2: Lower Detection Limits of HBV DNA Assays
  • Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by Technology
  • Table 3.4: Global Market for HBV Diagnostic Testing,
  • Table 3.5: U.S. Market for HBV Diagnostic Testing,
  • Table 3.6: Efficiency of Available HCV Screening Tests
  • Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C
  • Table 3.8: U.S. HCV Statistics
  • Table 3.9: Global Market for DNA HCV Diagnostic Testing,
  • Table 3.10: U.S. Market for DNA HCV Diagnostic Testing,
  • Table 3.11: Global Market for NAT HCV Diagnostic Testing,
  • Table 3.12: U.S. Market for NAT HCV Diagnostic Testing,
  • Table 3.13: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share,
  • Table 4.1: HPV Risk Factors
  • Table 4.2: HPV and Cervical Carcinoma
  • Table 4.3: Number of Pap Smears Performed by Country,
  • Table 4.4: Qiagen's Digene HC2 High-Risk HPV DNA Test
  • Table 4.5: Commercially Available Molecular Diagnostic Products for HPV Assay
  • Table 4.6: Long-Term Trends in HPV Testing
  • Table 4.7: Major Companies Marketing HPV Molecular Diagnostic Tests: Market Size and Share,
  • Table 4.8: Global Market for HPV Molecular Diagnostic Testing,
  • Table 4.9: U.S. Market for HPV Molecular Diagnostic Testing,
  • Table 5.1: HIV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact
  • Table 5.2: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact
  • Table 5.3: HIV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact
  • Table 5.4: Drivers of Demand for HIV Diagnostic Testing
  • Table 5.5: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact
  • Table 5.6: Summary of Assays for HIV Viral Load Testing
  • Table 5.7: Commercially Available Molecular Diagnostic Products for HIV Assay
  • Table 5.8: Global Market for Molecular Diagnostic HIV Diagnostic Testing,
  • Table 5.9: U.S. Market for Molecular Diagnostic HIV Diagnostic Testing,
  • Table 5.10: Global Market for HIV Viral Load Diagnostic Testing,
  • Table 5.11: U.S. Market for HIV Viral Load Diagnostic Testing,
  • Table 5.12: Global Market for HIV Viral Load Diagnostic Testing,
  • Table 5.13: U.S. Market for HIV Viral Load Diagnostic Testing,
  • Table 5.14: Competitive Factors Related to HIV Tests
  • Table 6.1: Rapid Strep Tests on the Market
  • Table 6.2: U.S. Chlamydia Infection Rates,
  • Table 6.3: Rapid Tests for Chlamydia
  • Table 6.4: Rapid Tests for Gonorrhea
  • Table 6.5: Global Market for Tuberculosis Molecular Diagnostic Testing,
  • Table 6.6: U.S. Market for Tuberculosis Molecular Diagnostic Testing,
  • Table 6.7: Commercially Available Molecular Diagnostic Products for MRSA Assay
  • Table 6.8: Global Market for MRSA Diagnostic Testing,
  • Table 6.9: U.S. Market for MRSA Diagnostic Testing,
  • Table 7.1: Medication Chart for Cardiovascular Disease
  • Table 7.2: Cardiac Marker Testing Market: Market Drivers Ranked in Order of Impact
  • Table 7.3: POC Cardiac Marker Testing Market: Market Restraints Ranked in Order of Impact
  • Table 7.4: BNP Clinical Characteristics
  • Table 7.5: FDA Approved BNP Assays
  • Table 7.6: FDA Approved NT-proBNP Assays
  • Table 7.7: BNP Clinical Characteristics
  • Table 7.8: Cardiovascular Risk Classification by CRP Level
  • Table 7.9: Cardiac Marker Markets by Country and Region,
  • Table 7.10: Cardiac Marker Markets by Country and Region,
  • Table 7.11: Total Global Cardiac Marker Market,
  • Table 8.1: Genetic Testing: Consequences and Challenges
  • Table 8.2: CF Carrier Risk by Ethnic Group
  • Table 8.3: Reasons for CF Testing
  • Table 8.4: CF Gene Detection Rates Vary by Ethnic Background
  • Table 8.5: Global Market for CF Diagnostic Testing,
  • Table 8.6: U.S. Market for CF Diagnostic Testing,
  • Table 9.1: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender,
  • Table 9.2: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender,
  • Table 9.3: Corporate Players Entering the Prostate Cancer Molecular Diagnostic Space
  • Table 9.4: Worldwide CA
  • Table 9.5: TPA Marker Sensitivity
  • Table 9.6: Overview of ER/PR Testing and Response to Therapy
  • Table 9.7: Overview of HER2/neu and Herceptin
  • Table 9.8: Breast Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
  • Table 9.9: Commercially Available Molecular Diagnostic Products for Ovarian Cancer Assay
  • Table 9.10: INFINITI Applications
  • Table 9.11: Global Revenue Forecasts for Cancer Marker Testing,
  • Table 10.1: Stat Urine Testing Drug Recommendations
  • Table 11.1: Global Revenue Forecasts for Vitamin D Testing,
  • Table 13.1: Global Distribution of IVD Testing by Key Geographic Regions,
  • Table 13.2: Top
  • Table 13.3: Company Market Share for IVD Testing Markets,
  • Table 13.4: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing,
  • Table 13.5: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region,
  • Table 13.6: Global IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 13.7: Summary of IVD High-Growth Market U.S.,
  • Table 13.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S.,
  • Table 13.9: U.S. Individual IVD High-Growth Markets Revenue Forecast
  • Table 13.10: Cardiac Markers in Clinical Use
  • Table 13.11: Cardiac Markers after Onset of Myocardial Infarction
  • Table 13.12: U.S. Cardiac Marker Market,
  • Table 13.13: U.S. Cardiac Marker Diagnostic Testing Market Segments,
  • Table 13.14: Market Share of Cardiac Marker Segment
  • Table 13.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Europe,
  • Table 13.16: Europe: Individual IVD High-Growth Markets Revenue Forecast,
  • Table 13.17: Europe: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 13.18: Cardiac Marker Market for Diagnostic Testing in Europe,
  • Table 13.19: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil,
  • Table 13.20: Brazil: Individual IVD High-Growth Markets Revenue Forecast,
  • Table 13.21: Brazil: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 13.22: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia,
  • Table 13.23: Russia: Individual IVD High-Growth Markets Revenue Forecast,
  • Table 13.24: Russia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 13.25: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India,
  • Table 13.26: India: Individual IVD High-Growth Markets Revenue Forecast,
  • Table 13.27: India: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 13.28: Disease Burden in China: Urban and Rural
  • Table 13.29: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China,
  • Table 13.30: China: Individual IVD High-Growth Markets Revenue Forecast,
  • Table 13.31: China: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 13.32: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Other Asia,
  • Table 13.33: Other Asia: Individual IVD High-Growth Markets Revenue Forecast,
  • Table 13.34: Other Asia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type,
  • Table 15.1: Medicare National Minimum Payment Amounts for Cervical Pathology Procedures
  • Table 16.1: New CPT Test Codes Introduced in
  • Table 19.1: Common Genotype Techniques
  • Table 20.1: Applications for Wireless LAN Technology
  • Table 20.2: Customized Reports Must Support CAP and JCAHO Requirements
  • Table 21.1: Biochip Revenues and Growth Rates by Application,
  • Table 21.2: Biochip Revenues and Growth Rates by Type,
  • Table 22.1: Drugs of Abuse Cut-off Levels for the TOX
Back to Top